论文部分内容阅读
最近,美国FDA批准拜耳制药公司(Miles Pharmaceuticals)的环丙氟哌酸(ciprofloxacin,Cipro)上市,它是迄今在美国市场上批准销售的第二个氟喹啉酮酸类(Fluroquinolone)抗菌剂。作为新的氟喹啉酮酸类抗菌剂,环丙氟哌酸抗菌谱广,抗菌活性强。研究结果表明,它可有效地治疗尿路感染(并发或非并发),淋球菌感染,各种软组织感染,敏感菌引起的呼吸道感染,骨髓炎,细菌血症以及用于清除肠道细菌,治疗胃肠感染。
Recently, the U.S. FDA approved the listing of ciprofloxacin (Cipro) from Miles Pharmaceuticals, the second fluroquinolone antibacterial marketed in the U.S. market to date. As a new fluoroquinolone acid antibacterial agent, Ciprofloxacin broad antibacterial spectrum, strong antibacterial activity. The results show that it can effectively treat urinary tract infection (concurrent or non-concurrent), Neisseria gonorrhoeae infection, a variety of soft tissue infections, respiratory infections caused by sensitive bacteria, osteomyelitis, bacteremia, and for the removal of intestinal bacteria, treatment Gastrointestinal infection.